EpiCast Report: Hodgkin S Lymphoma Epidemiology Forecast to 2024 Now Available at

iData Insights
EpiCast Report: Hodgkin s Lymphoma - Epidemiology Forecast to 2024 Summary Hodgkin s lymphoma (HL), also
known as Hodgkin s disease, is a type of lymphoma, a cancerous condition that affects the lymphatic system and
occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells,
called lymphocytes, which spreads beyond the lymphatic system and impairs the body s immune system. According
to the American Cancer Society (ACS), HL can start anywhere in the lymphoid tissue of body, but quite often starts in
the upper part of body with main sites in the neck, the chest, or under the arms. HL mostly spreads through lymph
vessels to other lymph nodes, and in advanced stages can even invade the bloodstream and spread to other organs
including the liver, lungs, and bone marrow. The most common symptoms of HL include enlarged lymph nodes under
the skin of the neck, under the arm, or in the groin, fever (which can come and go over several days or weeks)
without an infection; drenching night sweats, and weight loss. To forecast the diagnosed incident cases and five-year
diagnosed prevalent cases of HL in 7MM, GlobalData epidemiologists obtained data from population-based studies
that provided country-specific data in each of the 7MM. In addition, GlobalData epidemiologists used the staging
system for HL known as the Cotswold system, which is a modification of the older Ann Arbor system, to segment the
diagnosed incident cases of HL in the 7MM into stages I, II, III, and IV. GlobalData epidemiologists forecast an
increase in the diagnosed incident cases of HL in the 7MM from 23,662 diagnosed incident cases in 2014 to 28,397
diagnosed incident cases in 2024 at an Annual Growth Rate (AGR) of 2%. The increase in the diagnosed incident
cases of HL was partly attributed to the moderately rising trend in the incidence of HL in the 7MM, combined with
changes in the population demographics in the respective markets. Scope - The Hodgkin s Lymphoma (HL)
EpiCast Report provides an overview of the risk factors and global trends of HL in the 7MM (US, France, Germany,
Italy, Spain, UK and Japan). It includes a 10-year epidemiology forecast for the diagnosed incident cases of HL,
segmented by age, sex, and clinical stage at diagnosis, and types (classical HL and nodular lymphocyte predominant
HL, with classical HL further segmented into subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich,
and lymphocyte-depleted) in these markets. In addition, GlobalData epidemiologists provide a 10-year
epidemiological forecast for the five-year diagnosed prevalent cases of HL, as well as the number of HL diagnosed
incident cases refractory to chemo- and radiation therapy, the number of HL diagnosed incident cases who received
autologous stem cell transplantation (ASCT), and HL diagnosed incident cases refractory to ASCT from 2014-2024 in
these markets. - The HL epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease
trends in the 7MM. Reasons to buy The Hodgkin s Lymphoma (HL) EpiCast series will allow you to - - Develop
business strategies by understanding the trends shaping and driving the global HL market. - Quantify patient
populations in the global HL market to improve product design, pricing, and launch plans. - Organize sales and
marketing efforts by identifying the age groups and sex that present the best opportunities for HL therapeutics in each
of the markets covered. - Identify the percentage of HL diagnosed incident cases by type and treatment.
Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=124183/epicastreport-dry-eye-syndrome-epidemiology-forecast-to-2024
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landing-page.php?id=124183/epicastreport-dry-eye-syndrome-epidemiology-forecast-to-2024
Table of Contents
1 Table of Contents
4 1.1 List of Tables
6 1.2 List of Figures
7 2 Introduction
8 2.1 Catalyst
8 2.2 Related Reports
9 2.3 Upcoming Related Reports

10 3 Epidemiology
11 3.1 Disease Background
11 3.2 Risk Factors and Comorbidities
12 3.3 Global Trends
14 3.3.1 Incidence
14 3.3.2 Survival Rates for HL

7MM

16 3.4 Forecast Methodology

17 3.4.1 Sources Used
21 3.4.2 Sources Not Used
23 3.4.3 Forecast Assumptions and Methods, HL Diagnosed Incident Cases
24 3.4.4 Forecast Assumptions and Methods, HL Five-Year Diagnosed Prevalent Cases
24 3.4.5 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Clinical Stages at Diagnosis
25 3.4.6 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Cellular Types
26 3.4.7 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Refractory/Relapse to CRT % 7MM
27 3.4.8 Forecast Assumptions and Methods, HL Diagnosed Incident Cases Who Received ASCT
27 3.4.9 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Refractory/Relapse to ASCT
28 3.5 Epidemiological Forecast for HL (2014-2024)
29 3.5.1 Diagnosed Incident Cases of HL
29 3.5.2 Age-Specific Diagnosed Incident Cases of HL
30 3.5.3 Sex-Specific Diagnosed Incident Cases of HL
32 3.5.4 Age-Standardized Diagnosed Incidence of HL
34 3.5.5 Diagnosed Incident Cases of HL by Clinical Stage at Diagnosis
35 3.5.6 Diagnosed Incident Cases of HL by Cellular Types
36 3.5.7 Diagnosed Incident Cases of HL, Refractory/Relapse to CRT
37 3.5.8 Diagnosed Incident Cases of HL, Receiving ASCT
38 3.5.9 Diagnosed Incident Cases of HL, Refractory to ASCT
39 3.5.10 Five-Year Diagnosed Prevalent Cases of HL
40 3.6 Discussion
42 3.6.1 Epidemiological Forecast Insight
42 3.6.2 Limitations of the Analysis
42 3.6.3 Strengths of the Analysis
43 4 Appendix 44 4.1 Bibliography
44 4.2 About the Authors

47 4.2.1 Epidemiologist
47 4.2.2 Reviewers
47 4.2.3 Global Director of Therapy Analysis and Epidemiology
48 4.2.4 Global Head of Healthcare
49 4.3 About GlobalData
50 4.4 About EpiCast
50 4.5 Disclaimer
Read More @ http://www.idatainsights.com/reports-landing-page.php?id=124183/epicast-report-dry-eye-syndromeepidemiology-forecast-to-2024
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research
information aggregator and marketing research consulting firm. We conduct both primary and secondary research.
Our work does not end with research it is also involved in distributing reports for different companies . We provide
actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be
a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that
will make a difference to their bottom line.

Contact Us:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com

About iData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to
provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our
promise to provide results that are essential to the success of your company. We believe that by doing so, we will
earn the trust of our clients for future projects.